我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
62
47 进行中
药物批准
2
批准总数
监管机构
监管机构数
成立时间
2000
进行中（未招募）
47
75.8%
Approved For Marketing
1
1.6%
已完成
3
4.8%
招募中
终止
7
11.3%
撤回
EMA
European Medicines Agency
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
- Two real-world evidence studies from Spain and Italy demonstrate Pepaxti's effectiveness in heavily pretreated relapsed or refractory multiple myeloma patients at the IMS Annual Meeting. - The Italian study reports a 47% overall response rate in patients who had received multiple prior therapies, including novel immunotherapies targeting BCMA and GPRC5D. - Both studies confirm Pepaxti's favorable safety profile in real-world clinical settings, providing crucial evidence for treatment decisions outside controlled trial environments. - The data underscore growing physician confidence in Pepaxti's clinical utility, particularly in later lines of therapy where treatment options are limited.
